A PHASE 1, OPEN-LABEL, SINGLE-DOSE, CROSSOVER STUDY TO ASSESS THE BIOEQUIVALENCE UNDER FED AND FASTED CONDITIONS OF FESOTERODINE BEADS-IN-CAPSULE SR7 AND SR4 FORMULATIONS, THE EFFECT OF FOOD ON THE PHARMACOKINETICS OF THE BEADS-IN-CAPSULE SR7 FORMULATION AND TO ESTIMATE THE BIOAVAILABILITY OF SR7 BEADS SPRINKLED ON APPLE SAUCE RELATIVE TO THE BEADS-IN-CAPSULE SR7 FORMULATION ADMINISTERED INTACT
Latest Information Update: 12 Feb 2021
At a glance
- Drugs Fesoterodine (Primary)
- Indications Overactive bladder
- Focus Pharmacokinetics
- Sponsors Pfizer
- 08 Feb 2021 Status changed from recruiting to completed.
- 11 Aug 2020 Planned End Date changed from 19 Mar 2021 to 18 Mar 2021.
- 11 Aug 2020 Planned primary completion date changed from 19 Mar 2021 to 18 Mar 2021.